World Medicine at CPHI Frankfurt 2022

The World Pharmaceutical Congress and Exhibition (CPHI), held annually in Frankfurt, Germany, which has become one of the key meeting points of the pharmaceutical industry, took place on November 1-3. World Medicine, which has been operating in Türkiye since 2011, welcomed visitors at its 124 m2 stand. Stating that they had taken their place at the international exhibition that brings together pharmaceutical manufacturers and distributors, Ruşen Kalender, Chairman of the Board of Directors of World Medicine, said, “We are working intensively to export the medicines we manufacture in Türkiye to the world, while continuing our investments without slowing down. Our greatest goal is to become the company exporting the highest volume of pharmaceuticals from Türkiye. In line with this goal, we took our place in this important organization, as we do every year.”

A total of 2,500 international pharmaceutical, machinery, and raw material manufacturers from 170 countries participated in CPHI Frankfurt 2022, including 34 pharmaceutical companies from Türkiye. The exhibition came to an end on November 3.

Emphasizing that they are accelerating their initiatives every day to increase the number of countries to which they export, in addition to the products they offer to the Turkish market, Ruşen Kalender, Chairman of the Board of Directors of World Medicine, said, “Being a reliable business partner and a leading company in every country and field in which we operate is of great importance to us. We are strengthening our infrastructure for greater pharmaceutical exports and working intensively to increase our manufacturing capacity through our state-of-the-art production facilities and to export the medicines we manufacture in Türkiye to the world. In this context, we received strong interest at CPHI Frankfurt, which we attend every year. Seeing the return of our investments and efforts makes us extremely proud.”

We grow through our investments

Stating that they continue to grow by increasing their investments every year, Kalender said, “We are strengthening our infrastructure to increase the number of countries to which we export. At our Tekirdağ Çerkezköy factory, the flagship of our pharmaceutical manufacturing investments, we produce liquid sterile forms, lyophilized sterile forms, solid forms, semi-solid forms, and non-sterile liquid forms. At the same time, we continue to invest in our factories and expand our manufacturing capacity. We have initiated the स्थापना and commissioning works for our Cephalosporin (CEF) Manufacturing Facility. Most recently, we also began work on our additional production facility, for which we laid the foundation in recent days with an investment of approximately TRY 700 million. Once the facility is completed, we will have a total enclosed area of 23,300 square meters.”